$1.07 Billion is the total value of Rock Springs Capital Management LP's 105 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | GILEAD SCIENCES INC | $25,023,000 | +4.1% | 255,000 | 0.0% | 2.34% | -16.8% | |
| RCPT | RECEPTOS INC | $10,718,000 | +34.6% | 65,000 | 0.0% | 1.00% | +7.6% | |
| INCY | INCYTE CORP | $10,358,000 | +25.4% | 113,000 | 0.0% | 0.97% | +0.3% | |
| COO | COOPER COS INC | $10,121,000 | +15.6% | 54,000 | 0.0% | 0.95% | -7.5% | |
| RTIX | RTI SURGICAL INC | $9,188,000 | -5.0% | 1,860,000 | 0.0% | 0.86% | -24.0% | |
| DHR | DANAHER CORP DEL | $8,957,000 | -0.9% | 105,500 | 0.0% | 0.84% | -20.8% | |
| PRAH | PRA HEALTH SCIENCES INC | $8,219,000 | +19.1% | 285,000 | 0.0% | 0.77% | -4.7% | |
| WCG | WELLCARE HEALTH PLANS INC | $5,488,000 | +11.5% | 60,000 | 0.0% | 0.51% | -10.9% | |
| FGEN | FIBROGEN INC | $4,748,000 | +14.8% | 151,300 | 0.0% | 0.44% | -8.3% | |
| BLUE | BLUEBIRD BIO INC | $3,019,000 | +31.7% | 25,000 | 0.0% | 0.28% | +5.2% | |
| TRIV | TRIVASCULAR TECHNOLOGIES INC | $2,077,000 | -16.6% | 198,000 | 0.0% | 0.19% | -33.3% | |
| KIN | KINDRED BIOSCIENCES INC | $1,964,000 | -4.1% | 275,000 | 0.0% | 0.18% | -23.3% | |
| ROKA | ROKA BIOSCIENCE INC | $800,000 | -27.5% | 250,000 | 0.0% | 0.08% | -41.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.